Charles River Laboratories | CRL - Interest Expense On Debt

Stock Price
169.80
Daily Change
2.06 1.23%
Monthly
2.36%
Yearly
48.09%
Q2 Forecast
166.17

Charles River Laboratories reported $23.78M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Agilent USD 25M 2M Dec/2025
Align Technology USD 2M 660K Mar/2023
Bio-Rad Laboratories USD 12.3M 100K Sep/2025
Bruker USD 20M 4.3M Sep/2025
Cardinal Health USD 88M 8M Dec/2025
Charles River Laboratories USD 23.78M 1.63M Dec/2025
Cigna USD 157.92B 460K Dec/2025
Concord Medical Services Hldg CNY 84.37M 32.34M Jun/2023
CVS Health USD 787M 3M Dec/2025
Danaher USD 63M 8M Mar/2026
Dentsply International USD 22M 1000K Dec/2025
Elevance Health USD 357M 9M Mar/2026
Galapagos EUR 1.72M 940K Sep/2025
Humana USD 146M 22M Dec/2025
Illumina USD 25M 0 Sep/2025
Incyte USD 582K 10K Dec/2025
Intrexon USD 2K 5K Jun/2024
IQVIA Holdings USD 193M 4M Dec/2025
Laboratory Of America USD 55M 1000K Dec/2025
Lonza CHF 84M 14M Jun/2025
McKesson USD 63M 11M Dec/2025
Merck EUR 121M 5M Dec/2025
Mettler Toledo International USD 17.39M 307K Dec/2025
Novartis USD 304M 23M Dec/2025
Pfizer USD 711M 59M Dec/2025
Quest Diagnostics USD 69M 2M Sep/2025
Revvity USD 23.51M 742K Dec/2025
Thermo Fisher Scientific USD 354M 11M Mar/2026
United Therapeutics USD 3.1M 100K Dec/2025
UnitedHealth USD 955M 19M Mar/2026
Veradigm USD 1.25M 641K Sep/2022
Waters USD 8.62M 18.02M Dec/2025
West Pharmaceutical Services USD 1.9M 1.7M Mar/2026